Methodological aspects of estimating rare cancer prevalence in Europe: The experience of the RARECARE project

Cancer Epidemiology

Volumn 37, Issue 6, 2013, Pages 850-856

  Mallone, Sandra ^a   Angelis, Roberta De ^a   Zwan, Jan Maarten Vander ^b   Trama, Annalisa ^d   Siesling, Sabine ^b,c   Gatta, Gemma ^d   Capocaccia, Riccardo ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b Section of Epidemiology   (Netherlands)

^c UNIVERSITY OF TWENTE   (Netherlands)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Complete prevalence; Completeness index; Incidence; Rare cancer; Statistical model quality assessment; Survival

Indexed keywords

AGE DISTRIBUTION; ARTICLE; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER REGISTRY; CANCER SURVIVOR; EUROPE; GERIATRIC PATIENT; LETHALITY; METHODOLOGY; PRIORITY JOURNAL; RARE DISEASE; SURVIVAL RATE; VALIDATION STUDY;

COMPLETE PREVALENCE; COMPLETENESS INDEX; INCIDENCE; RARE CANCER; STATISTICAL MODEL QUALITY ASSESSMENT; SURVIVAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASMS; PREVALENCE; PROGNOSIS; RARE DISEASES; REGISTRIES; YOUNG ADULT;

EID: 84888295245     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2013.08.001     Document Type: Article

References (28)

1. Feldman A.R., Kessler L., Myers M.H., Naughton M.D. The prevalence of cancer. Estimates based on the Connecticut tumor registry. N Engl J Med 1986, 315:1394-1397.
2. Hakama M., Hakulinen T., Teppo L., Saxen E. Incidence, mortality and prevalence as indicators of the cancer problem. Cancer 1975, 36:2227-2231.
3. Adami H.O., Gunnarson T., Sparén P., Eklund G. The prevalence of cancer in Sweden 1984. Acta Oncol 1989, 28:463-470.
4. Gail M.H., Kessler L., Midthune D., Scoppa S. Two approaches for estimating disease prevalence from population-based registries of incidence and total mortality. Biometrics 1999, 55(4):1137-1144.
5. Colonna M., Hedelin G., Estève J., et al. National cancer prevalence estimation in France. Int J Cancer 1987, 2000:301-304.
6. Verdecchia A., Capocaccia R., Egidi V., Golini A. A method for the estimation of chronic disease morbidity and trends from mortality data. Stat Med 1989, 8:201-216.
7. Capocaccia R., De Angelis R. Estimating the completeness of prevalence based on cancer registry data. Stat Med 1997, 16:425-440.
8. Corazziari I., Mariotto A., Capocaccia R. Correcting the completeness bias of observed prevalence. Tumori 1999, 85:370-381.
9. Capocaccia R., Colonna M., Corazziari I., R.De Angelis, Francisci S., Micheli A., et al. Measuring cancer prevalence in Europe: the EUROPREVAL project. Ann Oncol 2002, 13(6):831-839.
10. Merrill R.M., Feuer E.J., Capocaccia R., Mariotto A. Cancer prevalence estimates based on tumor registry data in the SEER program. Int J Epidemiol 2000, 29:197-207.
11. Gatta G., van der Zwan J.M., Casali P.G., Siesling S., Dei Tos A.P., Kunkler I., et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer 2011, 47:2493-2511.
12. Pearce N. What does the odds ratio estimate in a case-control study?. Int J Epidemiol 1993, 22:1189-1192.
13. Armitage P., Doll R. The age distribution of cancer and a multi-stage theory of carcinogenesis. Br J Cancer 1954, 8:1-12.
14. Cook P.J., Doll R., Fellingham A. A mathematical model for the age distribution of cancer in man. Int J Cancer 1969, 4:93L 112.
15. De Angelis R., Capocaccia R., Hakulinen T., et al. Mixture models for cancer survival analysis: application to population-based data with covariates. Stat Med 1999, 18:441-454.
16. SAS software, version 9.1.3 2003, SAS - Statistical Analysis System Institute Inc, Cary, NC, USA.
17. NCI Seer*Stat - surveillance, epidemiology, and end results software 2010, Program of the National Cancer Institute, Version 7.0.2 http://seer.cancer.gov/seerstat/.
18. Hakulinen T. Cancer survival corrected for heterogeneity in patient withdrawal. Biometrics 1982, 38:933-942.
19. NCI ComPrev - complete prevalence software 2005, Program of the National Cancer Institute, Version 1.0 http://surveillance.cancer.gov/comprev/.
20. De Angelis R., Francisci S., Baili P., et al. The EUROCARE-4 database on cancer survival in Europe: data standardization, quality control and methods of statistical analysis. Eur J Cancer 2009, 45:909-930.
21. Forman D., Stockton D., Møller H., Quinn M., Babb P., De Angelis R., et al. Cancer prevalence in the UK: results from the EUROPREVAL study. Ann Oncol 2003, 14(4):648-654.
22. Capocaccia R., Colonna M., Corazziari I., De Angelis R., Francisci S., Micheli A., et al. Measuring cancer prevalence in Europe: the EUROPREVAL project. Ann Oncol 2002, 13:831-839.
23. Möller T., Anderson H., Aareleid T., Hakulinen T., Storm H., Tryggvadottir L., et al. Cancer prevalence in Northern Europe: results from the EUROPREVAL study. Ann Oncol 2003, 14(4):946-957.
24. Cancer incidence in five continents annual dataset 2013, http://ci5.iarc.fr/CI5plus/ci5plus.htm (accessed 20.05.13).
25. Ovarian cancer incidence statistics 2013, http://www.cancerresearchuk.org/cancer-info/cancerstats/types/ovary/incidence/ (accessed 25.05.13).
26. Ferlay J., Bray F., Pisani P., Parkin D.M. GLOBOCAN 2002 cancer incidence, mortality and prevalence worldwide IARC CancerBase 2004 No. 5, version 2.0 2004, IARC Press, Lyon.
27. The European partnership for action against cancer (EPAAC) 2013, http://www.epaac.eu/ (accessed 4.05.13).
28. European cancer health indicator project 2013, http://www.tumori.net/eurochip/ (accessed 4.05.13).